Earnings Summary

Bicycle Therapeutics Plc’s revenue jumped 160.32% since last year same period to $11.4Mn in the Q2 2023. On a quarterly growth basis, Bicycle Therapeutics Plc has generated 132.78% jump in its revenue since last 3-months.

Bicycle Therapeutics Plc’s net profit fell -58.8% since last year same period to $-42.6Mn in the Q2 2023. On a quarterly growth basis, Bicycle Therapeutics Plc has generated -9.06% fall in its net profits since last 3-months.

Bicycle Therapeutics Plc’s net profit margin jumped 39% since last year same period to -373.81% in the Q2 2023. On a quarterly growth basis, Bicycle Therapeutics Plc has generated 53.15% jump in its net profit margins since last 3-months.

Bicycle Therapeutics Plc’s earning per share (EPS) estimates for the current quarter stand at -1.05 - a -17.98% fall from last quarter’s estimates.

Bicycle Therapeutics Plc’s earning per share (EPS) estimates for the current year stand at -1.05.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bicycle Therapeutics Plc’s return on assets (ROA) stands at -0.2.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bicycle Therapeutics Plc’s return on equity (ROE) stands at -0.53.